Alisertib (MLN8237), Aurora A inhibitor (TBI4124)
Care information
Care information
Display general product information or specific product information using metafields.
Delivery and Shipping
Delivery and Shipping
Add some general information about your delivery and shipping policies.
Alisertib (MLN8237), Aurora A inhibitor (TBI4124)
Payment & Security
Payment methods
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Product Description
Description
Product Details
Formal Name: 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid
Alternate Names: MLN8237
Molecular Formula: C27H20ClFN4O4
Formula Weight: 518.90
CAS Number: 1028486-01-2
Purity: >98%
Formulation: powder
Solubility: Soluble in DMSO (up to 5 mg/ml)
Storage: -20°C
Stability: ≥ 1 year.
Applications
Aurora A inhibitor
Functions
Highly potent, ATP-competitive inhibitor selective for Aurora A kinase (Ki = 0.3 nM; IC50 = 6.7 nM) over Aurora B (IC50 = 1.5 µM); does not inhibit a large panel of other kinases. Also exhibits off-target binding of GABAA (IC50 = 0.49 µM), but no effects attributable to this binding were observed in rats. Disrupts the Aurora A / Myc complex, resulting in Myc degradation in Myc-amplified neuroblastomas. Inhibits tumor cell growth in vitro and in vivo, causing apoptosis and autophagy, disrupted mitosis, and increased chromosome alignment abnormalities.
Application Procedures
First dissolved in DMSO (up to 5 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.
